Objective The focus of Primomed is the translational medicinal approach of the SMEs, i.e. developing disease modifying therapeutics for high unmet medical needs in chronic inflammatory and degenerative disorders. The Primomed project utilizes well characterized non-human primate models so that the SMEs can capitalize on subsequent clinical successes of their therapeutic lead compounds. The main objectives of the project are (1) to demonstrate proof of concept that drug compounds of the SME’s are efficacious in primate models relevant for the diseases of interest and (2) to determine the immune responses in biological samples generated by the research activities in the different animal models. The power of the Primomed project is the creation of a consortium bringing together four small and early-stage biotech companies owning innovative and proprietary drugs and two of the most renowned European primate research centres that will perform research activities with the new disease modifying molecules of the SME’s.The disease areas of interest in Primomed are asthma, multiple sclerosis and Parkinson disease. Amakem’s Localized Drug Action approach would allow the use of ROCK inhibitors for the treatment of respiratory diseases, e.g. asthma, while avoiding the side effects resulting from systemic ROCK inhibition. By selectively targeting IL-23p19, Complix’ Alphabody is an intriguing candidate for therapy development of asthma and MS and may avoid some of the severe side effects of other currently available and tested anti-IL12/IL23p40 therapies. FFP’s PG102 would be a first in class molecule with a novel mechanism of action in treating chronic inflammatory conditions such as MS. sNRG would be a protein drug with disease modifying potential for the treatment of an unmet medical need in Parkinson’s disease.Primomed will result in progressing the compounds to the clinic, maximize the chance at eventual market authorization and answer the unmet medical need of millions of patients. Fields of science natural sciencesbiological scienceszoologymammalogyprimatologymedical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesbasic medicineneurologymultiple sclerosismedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronavirusesmedical and health sciencesbasic medicineneurologyparkinson Programme(s) FP7-SME - Specific Programme "Capacities": Research for the benefit of SMEs Topic(s) SME-2013-1 - Research for SMEs Call for proposal FP7-SME-2013 See other projects for this call Funding Scheme BSG-SME - Research for SMEs Coordinator AMAKEM NV EU contribution € 320 235,00 Address AGORALAAN GEBOUW ABIS BIOVILLE 3590 DIEPENBEEK Belgium See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Jack Veuskens (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (5) Sort alphabetically Sort by EU Contribution Expand all Collapse all COMPLIX NV Belgium EU contribution € 374 599,00 Address AGORALAAN BUILDING A BIS BIOVILLE 3590 DIEPENBEEK See on map Region Vlaams Gewest Prov. Limburg (BE) Arr. Hasselt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Thore Hettmann (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data FAST FORWARD PHARMACEUTICALS BV Netherlands EU contribution € 172 616,00 Address YALELAAN 46 3584 CM UTRECHT See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Mark De Boer (Mr.) Links Contact the organisation Opens in new window Total cost No data MIND-NRG SA Switzerland EU contribution € 354 550,00 Address RUE DE JARGONNANT 2 1207 GENEVE See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Bertrand Damour (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER Netherlands EU contribution € 6 000,00 Address LANGE KLEIWEG 161 2288 GJ Rijswijk Zh See on map Region West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage Activity type Research Organisations Administrative Contact Bert T Hart (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV Germany EU contribution € 6 000,00 Address HANSASTRASSE 27C 80686 Munchen See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Research Organisations Administrative Contact Andrea Zeumann (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
